Ligand id: 8694

Name: valbenazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 74.02
Molecular weight 418.28
XLogP 3.92
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
FDA breakthrough drug status for tardive dyskinesia (TD) was converted to full approval, as the first and only approved treatment for adults with this condition, in April 2017.
Mechanism Of Action and Pharmacodynamic Effects
SLC18A2 (VMAT2) transports monoamines, particularly neurotransmitters such as dopamine, norepinephrine, serotonin, and histamine, from cellular cytosol into synaptic vesicles. Prolongued use of typical antipsychotics or centrally acting dopamine receptor blocking antiemetics at high doses can predispose patients to the onset of tardive syndromes, such as tardive dyskinesia. Valbenazine acts to regulate the levels of dopamine release during nerve communication, with minimal impact on the other monoamines. This selectivity is predicted to reduce the off target side effects arising from excessive dopamine depletion.